4//SEC Filing
Olson Eric R 4
Accession 0001209191-23-022970
CIK 0001556263other
Filed
Apr 3, 8:00 PM ET
Accepted
Apr 4, 6:54 PM ET
Size
9.4 KB
Accession
0001209191-23-022970
Insider Transaction Report
Form 4
Olson Eric R
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2023-03-31+2,000→ 7,973 total - Tax Payment
Common Stock
2023-04-03$2.58/sh−623$1,607→ 7,350 total - Exercise/Conversion
Restricted Stock Units
2023-03-31−2,000→ 6,000 total→ Common Stock (2,000 underlying)
Footnotes (5)
- [F1]Represents shares of common stock received upon vesting of a restricted stock unit award.
- [F2]On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
- [F3]Represents shares used to cover tax withholding on a restricted stock unit release.
- [F4]Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- [F5]Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023.
Documents
Issuer
Syros Pharmaceuticals, Inc.
CIK 0001556263
Entity typeother
Related Parties
1- filerCIK 0001678149
Filing Metadata
- Form type
- 4
- Filed
- Apr 3, 8:00 PM ET
- Accepted
- Apr 4, 6:54 PM ET
- Size
- 9.4 KB